Literature DB >> 22080245

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.

L C Collins1, J D Marotti, S Gelber, K Cole, K Ruddy, S Kereakoglow, E F Brachtel, L Schapira, S E Come, E P Winer, A H Partridge.   

Abstract

Prior studies have suggested a higher prevalence of high grade, ER-negative, HER2-positive, and basal-like carcinomas in young women with breast cancer. However, the precise distribution of poor prognostic features in this population remains unclear. We examined the pathologic features and distribution of molecular phenotype in relation to patient age in a large group of young women (≤40 years) with invasive breast cancer. Medical records were reviewed for clinical characteristics, tumor stage, and receptor status. Pathologic features, including those features associated with basal-like carcinomas, were examined by central review. Using tumor grade and biomarker expression, cancers were categorized as luminal A (ER+ and/or PR+ and HER2-, histologic grade 1 or 2); luminal B (ER+ and/or PR+ and HER2+, or ER and/or PR+, HER2- and grade 3); HER2 (ER and PR- and HER2+); and triple negative (ER-, PR-, and HER2-). Among 399 women of ≤40 years, 33% had luminal A tumors, 35% luminal B, 11% HER2 (ER-negative), and 21% triple negative. Compared to published results for all breast cancers, a greater proportion of young women had luminal B tumors, and a lesser proportion had luminal A. There were no significant differences in molecular phenotype, tumor stage or grade among the different age groups of young women. However, this population of young women presented with a different distribution of molecular phenotypes compared to the general population of women with breast cancer. These findings may have implications with regard to the etiology and prognosis of breast cancer in young women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22080245     DOI: 10.1007/s10549-011-1872-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  81 in total

1.  Breast cancer in systemic lupus erythematosus.

Authors:  B Tessier Cloutier; A E Clarke; R Ramsey-Goldman; Y Wang; W Foulkes; C Gordon; J E Hansen; E Yelin; M B Urowitz; D Gladman; P R Fortin; D J Wallace; M Petri; S Manzi; E M Ginzler; J Labrecque; S Edworthy; M A Dooley; J L Senécal; C A Peschken; S C Bae; D Isenberg; A Rahman; G Ruiz-Irastorza; J G Hanly; S Jacobsen; O Nived; T Witte; L A Criswell; S G Barr; L Dreyer; G Sturfelt; S Bernatsky
Journal:  Oncology       Date:  2013-07-25       Impact factor: 2.935

Review 2.  Unique aspects of caring for young breast cancer patients.

Authors:  Raina M Ferzoco; Kathryn J Ruddy
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

3.  Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.

Authors:  Jennifer K Plichta; Samantha M Thomas; Rebecca Vernon; Oluwadamilola M Fayanju; Laura H Rosenberger; Terry Hyslop; E Shelley Hwang; Rachel A Greenup
Journal:  Breast Cancer Res Treat       Date:  2020-01-24       Impact factor: 4.872

4.  18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Panli Li; Xiuying Wang; Chongrui Xu; Cheng Liu; Chaojie Zheng; Michael J Fulham; Dagan Feng; Lisheng Wang; Shaoli Song; Gang Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-25       Impact factor: 9.236

5.  Being Pregnant and Diagnosed with Breast Cancer.

Authors:  Sibylle Loibl; Sileny N Han; Frederic Amant
Journal:  Breast Care (Basel)       Date:  2012-06-27       Impact factor: 2.860

6.  The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers.

Authors:  Mariana Fitarelli-Kiehl; Juliana Giacomazzi; Patricia Santos-Silva; Marcia Silveira Graudenz; Edenir Inez Palmero; Rodrigo Augusto Depieri Michelli; Maria Isabel Achatz; Cynthia Aparecida Bueno de Toledo Osório; Victor Evangelista de Faria Ferraz; Clarissa Gondim Picanço; Patricia Ashton-Prolla
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

7.  Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society.

Authors:  Sungmin Park; Ku Sang Kim; Jeong-Soo Kim; Wonshik Han; Byeong-Woo Park; Seokwon Lee; Ye Won Jeon; Se Kyung Lee; Jonghan Yu; Jeong Eon Lee; Seok Won Kim; Seok Jin Nam
Journal:  Med Oncol       Date:  2017-05-12       Impact factor: 3.064

8.  Breast Carcinoma in Young Women: No Evidence of Increasing Rates of Metastatic Breast Carcinoma in a Single Tertiary Center Review.

Authors:  Niamh Conlon; Jane Howard; Jeffrey Catalano; Meighan Gallagher; Lee K Tan; Adriana D Corben
Journal:  Breast J       Date:  2016-02-29       Impact factor: 2.431

Review 9.  Breast cancer in an 18-year-old female: A fatal case report and literature review.

Authors:  Maciej Jóźwik; Renata Posmyk; Marcin Jóźwik; Andrzej Semczuk; Magdalena Gogiel-Shields; Marta Kuś-Słowińska; Magdalena Garbowicz; Mark Klukowski; Jacek Wojciechowicz
Journal:  Cancer Biol Ther       Date:  2018-07-03       Impact factor: 4.742

10.  Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death.

Authors:  Dong Won Ryu; Chung Han Lee
Journal:  J Korean Surg Soc       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.